LY3839840
/ Sitryx
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
June 06, 2025
A First-In-Human Study of LY3839840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=140 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed
Trial completion
February 27, 2025
A First-In-Human Study of LY3839840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=178 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting
Enrollment open
November 15, 2024
A First-In-Human Study of LY3839840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=160 | Active, not recruiting | Sponsor: Eli Lilly and Company | N=112 ➔ 160
Enrollment change
August 27, 2024
A First-In-Human Study of LY3839840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=112 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Aug 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025
Trial completion date • Trial primary completion date
July 22, 2024
A First-In-Human Study of LY3839840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=112 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting
Enrollment closed
1 to 5
Of
5
Go to page
1